This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
5/7/2026
Okay. All right. And with regards to photon counting for the medical business, I think I heard you say that you have two OEMs where you're, you know, you're relatively far along with and you're talking to eight others. Is that correct?
Yeah. So let me clarify. So we've, the last several calls, we've talked about CT, photon counting for CT. Those were the two OEMs that I was mentioning. But I wanted to give a color beyond those two CT OEMs. By the way, we're seeking out, as we've said, we'd love to get a couple more, and we're working on that. But beyond that, in other modalities, so beyond CT, we're seeing there's activity with customers who are active, there's eight customers who are actively engaged with us in various other modalities for different kinds of applications, CBCT applications and DR and breast imaging and a variety of areas. So the applicability of this technology is expanding beyond CT into other areas as well. And we have OEMs that have now brought products to market and there are others that are working actively on it.
Okay. And for the two that are working with CT, when do you think we'd start to see those in the field?
You're reading a preview of the VREX Q2 2026 earnings call.
Free account.
